Recent studies regarding pancreatic cancer have revealed that SMARCD3 amplification in cancer stem cells and its ability to control metabolic and fatty acid pathways are linked to therapeutic resistance [14]. This evidence concerns the gene SMARCD3 and familial pancreatic carcinoma.